Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
Full Year Results 2024
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma to host meet the management and site visit in Columbus, Ohio
Press Release, Corporate
17 March 2025
- Hikma remains a constituent of the FTSE4Good Index Press Release, Corporate 16 July 2025 Hikma remains a constituent of the FTSE4Good Index
- Hikma launches Morphine Sulfate Injection, USP, in a prefilled syringe in the US Press Release, Product 14 July 2025 Hikma launches Morphine Sulfate Injection, USP, in a prefilled syringe in the US
- Notice of results Press Release, Financial Results 09 July 2025 Notice of results
- Supporting communities globally: Highlights from our 2025 Global Volunteer Campaign Story, Responsibility 03 July 2025 Supporting communities globally: Highlights from our 2025 Global Volunteer Campaign
